CE vs ESPR · rev $10.28B vs rev $332.3M
Celanese Corporation (CE) versus Esperion Therapeutics Inc (ESPR) — a side-by-side from cached financials, not a winner call.
Celanese Corporation (CE) is a chemicals company listed on US.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported CE revenue for 2024-12-31 was $10.28B. Net income was -$1.51B. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. CE currently screens at market cap $5.92B.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
CE currently screens at market cap $5.92B. ESPR currently screens at market cap $816.9M.
Not investment advice. Open the CE and ESPR stock pages for the full models.
Not investment advice.